Compounds > bendamustine hydrochloride
Page last updated: 2024-08-25

bendamustine hydrochloride and 2019 Novel Coronavirus Disease

bendamustine hydrochloride has been researched along with 2019 Novel Coronavirus Disease in 5 studies

Research

Studies (5)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's5 (100.00)2.80

Authors

AuthorsStudies
Asakura, S; Saito, T; Ueda, Y; Wada, S; Yano, T1
Assanto, GM; Capriata, M; D'Elia, GM; Del Giudice, I; Di Rocco, A; Gentile, G; Girardi, P; Malfona, F; Martelli, M; Micozzi, A; Petrucci, L; Pulsoni, A1
Ishio, T; Izumiyama, K; Kobayashi, M; Kondo, T; Mori, A; Morioka, M; Muraki, H; Saito, M; Tsukamoto, S; Yokoyama, E1
Bedini, A; Bettelli, F; Dolci, G; Franceschini, E; Fregni-Serpini, G; Grottola, A; Guaraldi, G; Luppi, M; Meschiari, M; Mussini, C; Pecorari, M; Pellegrino, M; Perno, CF; Sarti, M; Todisco, V1
Andreu-Ullrich, H; Beigelman-Aubry, C; Comte, D; Dumas, D; Eckerle, I; Fenwick, C; Gachoud, D; Germann, D; Guery, B; Infanti, L; Jaton, K; Mean, M; Monti, M; Pellaton, C; Prella, M; Rufer, N; Stadelmann, R; Stamm, GM; Vollenweider, P; Zimmerli, A1

Other Studies

5 other study(ies) available for bendamustine hydrochloride and 2019 Novel Coronavirus Disease

ArticleYear
Prolonged COVID-19 in an Immunocompromised Patient Treated with Obinutuzumab and Bendamustine for Follicular Lymphoma.
    Internal medicine (Tokyo, Japan), 2022, Aug-15, Volume: 61, Issue:16

    Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; COVID-19; Humans; Immunocompromised Host; Lymphoma, Follicular; Rituximab; SARS-CoV-2

2022
Impact of anti-SARS-CoV-2 monoclonal antibodies in the management of patients with lymphoma and COVID19: A retrospective study.
    Hematological oncology, 2023, Volume: 41, Issue:3

    Topics: Antibodies, Monoclonal; Bendamustine Hydrochloride; COVID-19; Humans; Lymphoma; Retrospective Studies; SARS-CoV-2

2023
Anti-CD20 antibodies and bendamustine attenuate humoral immunity to COVID-19 vaccination in patients with B-cell non-Hodgkin lymphoma.
    Annals of hematology, 2023, Volume: 102, Issue:6

    Topics: Antibodies, Monoclonal, Murine-Derived; Antibodies, Viral; Bendamustine Hydrochloride; COVID-19; COVID-19 Vaccines; Humans; Immunity, Humoral; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2; Vaccination

2023
Persistent SARS-CoV-2 infection with multiple clinical relapses in two patients with follicular lymphoma treated with bendamustine and obinutuzumab or rituximab.
    Infection, 2023, Volume: 51, Issue:5

    Topics: Antineoplastic Combined Chemotherapy Protocols; Bendamustine Hydrochloride; COVID-19; Hematologic Neoplasms; Humans; Lymphoma, Follicular; Neoplasm Recurrence, Local; Rituximab; SARS-CoV-2

2023
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery.
    Frontiers in immunology, 2021, Volume: 12

    Topics: Aged; Antibodies, Neutralizing; Antibodies, Viral; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Immunological; Bendamustine Hydrochloride; COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Diabetes Mellitus, Type 2; Humans; Immunization, Passive; Immunoglobulin A; Immunoglobulin G; Immunoglobulin M; Immunosuppression Therapy; Leukemia, Lymphoid; Male; Rituximab; SARS-CoV-2; Treatment Outcome

2021